Low dose ribavirin has been effective in the treatment of incapacitating muco-cutaneous extrahepatic manifestations in patients with hepatitis C with contraindication or no access for approved antiviral treatment

Arab Journal of Gastroenterology

Volumn 16, Issue 3-4, 2015, Pages 125-128

  Esmail, Eslam Saber ^a   Asal, Fat Heyah Elsayed ^a   Yussif, Mohammed ^a   Elfert, Asem Ahmed ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Extrahepatic manifestations; HCV; Ribavirin

Indexed keywords

INTERFERON; RIBAVIRIN; STEROID; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; EGYPT; FEMALE; HEALTH SURVEY; HUMAN; LEUCOCYTOCLASTIC VASCULITIS; LICHEN PLANUS; LOW DRUG DOSE; MALE; MONOTHERAPY; PEMPHIGOID; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; TREATMENT CONTRAINDICATION; ULCERATING VASCULITIS; VASCULITIS; ADULT; AGED; COMPLICATION; DOSE RESPONSE; HEALTH CARE DELIVERY; MIDDLE AGED; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; VASCULITIS, LEUKOCYTOCLASTIC, CUTANEOUS;

ADULT; AGED; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C, CHRONIC; HUMANS; LICHEN PLANUS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; RIBAVIRIN; VASCULITIS, LEUKOCYTOCLASTIC, CUTANEOUS;

EID: 84959266881     PISSN: 16871979     EISSN: 20902387     Source Type: Journal    
DOI: 10.1016/j.ajg.2015.09.012     Document Type: Article

References (20)

1. Alter M.J. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007, 13(17):2436-2441.
2. Alavian S.M. Hepatitis C infection in Iran; a review article. Iran J Clin Infect Dis 2009, 4(1):47-59.
3. Kaldor J.M., Dore G.J., Correll P.K. Public health challenges in hepatitis C virus infection. J Gastroenterol Hepatol 2000, 15(Suppl.):E83-E90.
4. Patrick D.M., Buxton J.A., Bigham M., et al. Public health and hepatitis C. Can J Public Health 2000, 91(Suppl. 1):S18-S21. S19-23.
5. Prati F., Lodi V., D'Elia V., et al. Screening of health care workers for hepatitis B virus and hepatitis C virus: criteria for fitness for work (abstract). Arh Hig Rada Toksikol 2000, 51(1):19-26.
6. Alavian S.M., Kabir A., Ahmadi A.B., et al. Hepatitis C infection in hemodialysis patients in Iran: a systematic review. Hemodial Int 2010, 14(3):253-262.
7. El-Zanaty, Fatma, Ann Way Egypt Demographic and Health Survey 2008 2009, Ministry of Health, El-Zanaty and Associates, and Macro International, Cairo, Egypt, Quoted from:
8. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011, 13(2):107-115.
9. Raslan H.M., Ezzat W.M., Abd El Hamid M.F., Emam H., Amre K.S. Skin manifestations of chronic HCV infection in Cairo. Egypt East Mediterr Health J 2009, 15(3):692-700.
10. Lewis V., Finlay A.Y. 10 years experience of the dermatology life quality index (DLQI). J Investig Dermatol Symp Proc 2004, 9:169-180.
11. Clifford B.D., Donahue D., Smith L., et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995, 21:613-619.
12. Nagao Y., Sata M., Fukuizumi K., et al. High incidence of oral lichen planus in an HCV hyperendemic area. Gastroenterology 2000, 119:882-883.
13. Arrieta J.J., Rodriguez-Inigo E., Casqueiro M., et al. Detection of hepatitis C virus replication by in situ hybridization in epithelial cells of anti-hepatitis C virus-positive patients with and without oral lichen planus. Hepatology 2000, 32(1):97-103.
14. Mignogna M.D., Lo Muzio L., Lo Russo L., et al. Oral lichen planus: different clinical features in HCV-positive and HCV negative patients. Int J Dermatol 2000, 39:134-139.
15. Dixit N.M., Layden-Almer J.E., Layden T.J., et al. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004, 432:922.
16. Brok J., Gluud L.L., Gluud C. Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials. Am J Gastroenterol 2006, 101:842.
17. Di Bisceglie A.M., Conjeevaram H.S., Fried M.W., et al. Ribavirin as therapy for chronic hepatitis C; a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995, 123:897.
18. Bodenheimer H.C., Lindsay K.L., Davis G.L., et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997, 26:473.
19. Dusheiko G., Main J., Thomas H., et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996, 25:591.
20. Flamm S, Chopra S. Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection. Up to date CD-ROM 21.2 2012; Topic 3654.